"Bak (and Bax) to the future" - Of primary melanoma prognosis?

Journal of Investigative Dermatology

Volumn 126, Issue 6, 2006, Pages 1212-1214

  Leverkus, Martin ^a   Gollnick, Harald ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER GROWTH; HUMAN; MELANOMA; MITOCHONDRION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; DRUG ANTAGONISM; GENETICS; METABOLISM; NOTE; SKIN DISEASE;

APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; HUMANS; MELANOMA; PROGNOSIS; SKIN DISEASES;

EID: 33745559424     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/sj.jid.5700239     Document Type: Note

References (17)

1. Andersen MH, Svane IM, Kvistborg P, Nielsen OJ, Balslev E, Reker S et al. (2005) Immunogenicity of Bcl-2 in patients with cancer. Blood 105:728-34
2. Bullani RR, Huard B, Viard-Leveugle I, Byers HR, Irmler M, Saurat JH et al. (2001) Selective expression of FLIP in malignant melanocytic skin lesions. J Invest Dermatol 117:360-4
3. Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N et al. (2005) Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 202:1691-701
4. Chudnovsky Y, Khavari PA, Adams AE (2005) Melanoma genetics and the development of rational therapeutics. J Clin Invest 115:813-24
5. Cory S, Huang DC, Adams JM (2003) The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 22:8590-607
6. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H et al. (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med 353:2135-47
7. Drewniok C, Kavuri S, Sprick MR, Haas T, Gollnick H, Walczak H et al. (2006) Downregulation of cFLIP sensitizes melanoma cells to TRAIL- or CD95L-mediated apoptosis. Exp Dermatol 15:237-8
8. Fecker LF, Geilen CC, Tchernev G, Trefzer U, Assaf C, Kurbanov BM (2006) Loss of proapoptotic Bcl-2-related multidomain proteins in primary melanomas is associated with poor prognosis. J Invest Dermatol 126:1366-1371
9. Kelley SK, Ashkenazi A (2004) Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol 4:333-9
10. Lavrik IN, Golks A, Krammer PH (2005) Caspases: pharmacological manipulation of cell death. J Clin Invest 115:2665-72
11. Leverkus M (2004) Imiquimod: unexpected killer. J Invest Dermatol 122:XV-XVI
12. Locksley RM, Killeen N, Lenardo MJ (2001) The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104:487-501
13. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA et al. (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435:677-81
14. Queirolo P, Acquati M, Kirkwood JM, Eggermont AM, Rocca A, Testori A (2005) Update: current management issues in malignant melanoma. Melanoma Res 15:319-24
15. Soengas MS, Lowe SW (2003) Apoptosis and melanoma chemoresistance. Oncogene 22:3138-51
16. Strasser A (2005) The role of BH3-only proteins in the immune system. Nat Rev Immunol 5:189-200
17. Ulrich J, Bonnekoh B, Bockelmann R, Schon M, Schon MP, Steinke R et al. (2004) Prognostic significance of detecting micrometastases by tyrosinase RT/PCR in sentinel lymph node biopsies: lessons from 322 consecutive melanoma patients. Eur J Cancer 40:2812-9